Recursion Pharmaceuticals (RXRX) Asset Writedowns and Impairment (2022 - 2025)

Recursion Pharmaceuticals has reported Asset Writedowns and Impairment for 4 years, with the latest figure at $6.0 million in Q1 2025.

• For the quarter ending Q1 2025, Asset Writedowns and Impairment rose 5414.81% year-over-year to $6.0 million; the trailing twelve-month figure through Dec 2025 stood at $6.0 million (up 5414.81% YoY), and the FY2025 full-year result was $6.0 million, up 5414.81% from the prior year.
• Asset Writedowns and Impairment for Q1 2025 stood at $6.0 million, up from $108000.0 in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $6.0 million in Q1 2025, with the low at $19000.0 in Q3 2023.
• Historically, Asset Writedowns and Impairment has averaged $2.0 million across 4 years, with a median of $1.2 million in 2023.
• Annual changes were most pronounced in 2024 — Asset Writedowns and Impairment plunged 90.76% — and 2025, when it soared 5414.81%.
• Recursion Pharmaceuticals' Asset Writedowns and Impairment stood at $2.8 million in 2022, then sank by 99.32% to $19000.0 in 2023, then surged by 468.42% to $108000.0 in 2024, then surged by 5414.81% to $6.0 million in 2025.
• The last three Asset Writedowns and Impairment figures came in at $6.0 million (Q1 2025), $108000.0 (Q1 2024), and $19000.0 (Q3 2023), per Business Quant data.